Spruce Biosciences (SPRB) Competitors $0.07 0.00 (-3.61%) As of 03:22 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. PHXM, HCWB, DWTX, LSB, APRE, PHIO, TLPH, CYCN, ORGS, and GNPXShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include PHAXIAM Therapeutics (PHXM), HCW Biologics (HCWB), Dogwood Therapeutics (DWTX), Lakeshore Biopharma (LSB), Aprea Therapeutics (APRE), Phio Pharmaceuticals (PHIO), Talphera (TLPH), Cyclerion Therapeutics (CYCN), Orgenesis (ORGS), and Genprex (GNPX). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Its Competitors PHAXIAM Therapeutics HCW Biologics Dogwood Therapeutics Lakeshore Biopharma Aprea Therapeutics Phio Pharmaceuticals Talphera Cyclerion Therapeutics Orgenesis Genprex Spruce Biosciences (NASDAQ:SPRB) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Which has higher valuation and earnings, SPRB or PHXM? PHAXIAM Therapeutics has higher revenue and earnings than Spruce Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M0.64-$47.92M-$1.32-0.06PHAXIAM Therapeutics$32.66M0.32-$240KN/AN/A Does the media refer more to SPRB or PHXM? In the previous week, Spruce Biosciences had 3 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 4 mentions for Spruce Biosciences and 1 mentions for PHAXIAM Therapeutics. Spruce Biosciences' average media sentiment score of 0.36 beat PHAXIAM Therapeutics' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PHAXIAM Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, SPRB or PHXM? Spruce Biosciences has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Do analysts prefer SPRB or PHXM? Spruce Biosciences currently has a consensus target price of $1.75, suggesting a potential upside of 2,242.70%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Spruce Biosciences is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in SPRB or PHXM? Spruce Biosciences received 39 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformSpruce BiosciencesOutperform Votes3954.17% Underperform Votes3345.83% PHAXIAM TherapeuticsN/AN/A Do institutionals & insiders hold more shares of SPRB or PHXM? 91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 6.9% of Spruce Biosciences shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is SPRB or PHXM more profitable? PHAXIAM Therapeutics has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. PHAXIAM Therapeutics' return on equity of 0.00% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% PHAXIAM Therapeutics N/A N/A N/A SummarySpruce Biosciences beats PHAXIAM Therapeutics on 9 of the 14 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.16M$6.88B$5.58B$8.50BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-0.088.5527.1919.64Price / Sales0.64262.61408.78152.17Price / CashN/A65.8538.3234.64Price / Book0.046.536.974.60Net Income-$47.92M$143.48M$3.23B$248.06M7 Day PerformanceN/A0.20%-0.88%-1.02%1 Month PerformanceN/A10.93%7.81%3.51%1 Year PerformanceN/A2.46%31.53%12.68% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences2.4115 of 5 stars$0.07-3.6%$1.75+2,242.7%-88.3%$3.16M$4.91M-0.0820News CoverageShort Interest ↑PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049News CoverageHCWBHCW Biologics3.4341 of 5 stars$7.21-6.7%$35.00+385.4%-87.5%$10.38M$1.45M-7.2140Short Interest ↓Gap DownDWTXDogwood Therapeutics2.0114 of 5 stars$5.27+1.7%$10.00+89.8%N/A$10.07MN/A-0.805LSBLakeshore Biopharma0.6345 of 5 stars$1.07flatN/AN/A$9.96M$672.27M0.00773APREAprea Therapeutics3.2385 of 5 stars$1.80+3.4%$15.50+761.1%-54.8%$9.96M$580K-0.647Positive NewsShort Interest ↑High Trading VolumePHIOPhio Pharmaceuticals3.7541 of 5 stars$2.05+2.5%$4.00+95.1%-61.8%$9.84MN/A-0.1910Short Interest ↓Gap DownTLPHTalphera2.447 of 5 stars$0.48-2.6%$5.00+945.8%-48.3%$9.80M$27K-0.6919CYCNCyclerion Therapeutics1.8793 of 5 stars$2.96+5.3%N/A+36.6%$9.50M$2.08M-2.5530ORGSOrgenesis1.5526 of 5 stars$1.95+0.4%N/AN/A$9.35M$662K0.00150Gap UpGNPXGenprex1.4685 of 5 stars$0.32-4.4%N/A-87.7%$8.88MN/A0.0020Short Interest ↑ Related Companies and Tools Related Companies PHAXIAM Therapeutics Competitors HCW Biologics Competitors Dogwood Therapeutics Competitors Lakeshore Biopharma Competitors Aprea Therapeutics Competitors Phio Pharmaceuticals Competitors Talphera Competitors Cyclerion Therapeutics Competitors Orgenesis Competitors Genprex Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
